Skip to content
10-Q

Quarterly Report

Ernexa Therapeutics Inc. ERNA ERNAW

0001641172-25-009044

← back to feed
Filed
May 7, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 7, 2025 62.36M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $1.92M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $5.12M
Current Liabilities Q1 2025 · Mar 31, 2025 $10.44M
Current Liabilities Q1 2025 · Dec 31, 2024 $2.94M
Total Liabilities Q1 2025 · Mar 31, 2025 $11.01M
Total Liabilities Q1 2025 · Dec 31, 2024 $3.57M
Current Assets Q1 2025 · Mar 31, 2025 $2.21M
Current Assets Q1 2025 · Dec 31, 2024 $2.35M
Total Assets Q1 2025 · Mar 31, 2025 $5.06M
Total Assets Q1 2025 · Dec 31, 2024 $5.27M
Shares Diluted Q1 2025 · Mar 31, 2024 5.41M sh
Capex Q1 2025 · Mar 31, 2024 $101K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$3.75M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$3.41M
Stockholders Equity Q1 2025 · Dec 31, 2023 $2.23M
Eps Diluted Q1 2025 · Mar 31, 2024 −$1.23
Eps Basic Q1 2025 · Mar 31, 2024 −$1.23
Net Income Q1 2025 · Mar 31, 2024 −$6.65M
Operating Income Q1 2025 · Mar 31, 2024 −$5.79M
Gross Profit Q1 2025 · Mar 31, 2024 −$14K
Cost Of Revenue Q1 2025 · Mar 31, 2024 $61K